Back to search results

Advanced Imaging for Glioblastoma

This study is looking at new ways to use advanced MRI (magnetic resonance imaging) techniques to understand glioblastoma, a type of brain tumor. Researchers are testing three specific MRI methods: Chemical Exchange Saturation Transfer (CEST) MRI, Diffusion-Relaxation Correlation Spectrum Imaging (DR-CSI), and Ferumoxytol-enhanced MRI (Fe-MRI). They want to see if these techniques can effectively show the "tumor immune microenvironment" – the cells and proteins around the tumor that influence how it grows and responds to treatment. You might be able to join if you are 18 or older, have a confirmed or suspected glioblastoma diagnosis, are scheduled for surgery or biopsy, and have a measurable tumor. The goal is to see if these imaging methods can accurately assess this microenvironment. The study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 15 participants. The phase of the study is not specified.
What's involved
You would undergo research CEST MRI and DR-CSI, receive ferumoxytol intravenously, and then have an Fe-MRI. You would also have blood samples collected and standard clinical MRI scans.
Compensation
Not stated in the trial record.
Follow-up
After the study interventions, participants are followed up until death.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07461948

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

Recruiting
PHASE3Ages 18+InterventionalDiagnostic
Jonsson Comprehensive Cancer Center
~15 participants
Updated 2026-03-10 on ClinicalTrials.gov
What's tested:Biospecimen CollectionChemical Exchange Saturation Transfer Magnetic Resonance ImagingDiffusion-Relaxation Correlation Spectrum ImagingElectronic Health Record ReviewFerumoxytolMagnetic Resonance Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean diffusion-relaxation correlation spectrum imaging (DR-CSI) value
Measured over perioperatively/periprocedurally
+2 more outcomes measured

Conditions

Glioblastoma

Explore related trials

Glioblastoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Jingwen Yao · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

Jingwen Yao
[email protected]
310-869-2156
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female ≥ 18 years of age
Documentation of a confirmed or suspected diagnosis of glioblastoma
The participant is scheduled to undergo standard of care surgical tumor resection and/or biopsy
The participant has a measurable contrast-enhancing lesion (\> 1ml) based on the most recent MRI prior to resection/biopsy

Exclusion

Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Individuals who cannot tolerate MRI scan, or with contraindication to 3-Tesla (3T) MRI
Any abnormalities that would be a contraindication to iron-oxide nanoparticle-based contrast agent. Medical history will be gathered from the patient and clinical chart. The information will be reviewed with medical professionals (Doctor of Medicine \[MD\]) to determine the eligibility of the patient

What this trial measures

  • Mean diffusion-relaxation correlation spectrum imaging (DR-CSI) valueperioperatively/periprocedurally

    Mean DR-CSI values will be correlated with T cell densities. Pearson's or Spearman's correlation coefficients will be used depending on variable distributions.

  • Ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI) measuresperioperatively/periprocedurally

    Fe-MRI measures will be correlated with tumor-associated macrophage densities and iron staining concentration. Pearson's or Spearman's correlation coefficients will be used depending on variable distributions.

  • Chemical exchange saturation transfer (CEST) valuesperioperatively/periprocedurally

    CEST values will be correlated with tumor burden and immune suppression markers. Pearson's or Spearman's correlation coefficients will be used depending on variable distributions.